Different Treatment Options Used for Post Covid-19 Syndrome

NCT07722000 | Completed

• 1 other identifier: M 769
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to assess functioning during the recovery phase post-COVID-19 and to evaluate symptoms prolonging after COVID-19 infection and how to manage these symptoms.

Conditions

COVID-19; Post COVID-19 Syndrome; Ginkgo Biloba; Piracetam

Outcome Measures

Primary Outcomes (1)

• Mini-Mental State Examination (MMSE)

  The Mini-Mental State Examination (MMSE) was used to assess global cognitive status. It evaluates orientation, immediate and delayed recall, attention and calculation, language, and visuospatial construction. The total score ranges from 0 to 30, with higher scores reflecting better cognitive function. Cognitive impairment was classified as mild (21-24), moderate (10-20), or severe (\<10). The MMSE was administered in a face-to-face interview format

  1 year after the procedure

Secondary Outcomes (3)

• Fatigue Severity Scale

  1 year after the procedure

• Changes in headache severity

  1 year after the procedure

• Prevalence of neurological manifestations

  1 year post-procedure

Study Arms (3)

Group I

EXPERIMENTAL

Patients who received Ginkgo biloba alone.

Drug: Ginkgo biloba

Group II

EXPERIMENTAL

Patients who received piracetam alone.

Drug: Piracetam

Group III

EXPERIMENTAL

Patients who received a combination (Ginkgo biloba and Piracetam).

Drug: Ginkgo biloba and Piracetam

Interventions

Piracetam DRUG

Patients who received piracetam alone.

Group II

Ginkgo biloba and Piracetam DRUG

Patients who received a combination (Ginkgo biloba and Piracetam).

Group III

Ginkgo biloba DRUG

Patients who received Ginkgo biloba alone.

Group I

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged from 18 to 70 years.
• Both sexes.
• Positive diagnosis of COVID-19 within the last 3 months in relation to the time of assessment (COVID-19 diagnosis had been previously confirmed by RT-PCR nasal swab testing as part of routine clinical evaluation before enrollment into the study).

You may not qualify if:

• Patients with other non-COVID-related chronic illnesses that could interfere with the assessment of post-viral symptoms.
• Patients with pre-existing neurological disorders that could affect cognitive function or fatigue assessment, including dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, or prior cerebrovascular stroke, patients with diagnosed psychiatric disorders such as major depressive disorder, bipolar disorder, schizophrenia, or anxiety disorders requiring ongoing pharmacological treatment.
• Patients with uncontrolled endocrine disorders, particularly uncontrolled diabetes mellitus or thyroid dysfunction.
• Patients with malignancy or receiving chemotherapy, radiotherapy, or immunosuppressive therapy during the study period.
• Patients with chronic fatigue syndrome, fibromyalgia, or other pre-existing fatigue-related disorders diagnosed prior to SARS-CoV-2 infection.
• Patients with substance abuse or alcohol dependence, pregnant or lactating women.
• Patients with known hypersensitivity or contraindications to Ginkgo biloba or piracetam.
• Patients with poor adherence to treatment or anticipated inability to complete follow-up visits.

Sponsors & Collaborators

• Beni-Suef University: lead

Study Sites (1)

Beni Suef University

Banī Suwayf, Beni Suweif Governorate, 62511, Egypt

Location

MeSH Terms

Conditions

COVID-19; Post-Acute COVID-19 Syndrome

Interventions

Ginkgo Extract; Piracetam

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Post-Infectious Disorders; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Plant Extracts; Plant Preparations; Biological Products; Complex Mixtures; Acetamides; Amides; Organic Chemicals; Acetates; Acids, Acyclic; Carboxylic Acids; Pyrrolidinones; Pyrrolidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Bachelor degree in Pharmaceutical Sciences (Clinical Pharmacy), Beni- Suef University, Egypt.

Study Record Dates

• First Submitted: July 19, 2026
• First Posted: July 23, 2026
• Study Start: February 1, 2021
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2023
• Last Updated: July 28, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)